• This email address is being protected from spambots. You need JavaScript enabled to view it.

IMPAACT4HIV

Image

Improving Advanced HIV Disease Outcomes with IMPAACT4HIV

The Improved Access to AHD Care and Treatment for HIV (IMPAACT4HIV) project is a Unitaid-funded project dedicated to enhancing access to optimal diagnosis, prevention, treatment, and innovative delivery mechanisms for Advanced HIV Disease (AHD).

Despite significant investments in HIV, mortality rates remain unacceptably high, with one-quarter of HIV-related deaths occurring in sub-Saharan Africa. In 2022, 630,000 HIV-related deaths were reported globally, half of which were due to advanced HIV disease. This condition disproportionately affects children under five, who are at high risk of severe illness and death.

AHD challenges in Sub-Saharan Africa (SSA)

Despite notable progress towards the 2030 targets, Advanced HIV Disease remains a challenge in Sub-Saharan Africa particularly affecting children and adolescents.

Image

AHD affects 30% of ART naïve; 60% of people re-engaging in care.

Image

60% (380,000) the deaths reported in 2022 were in SSA.

Leading causes of mortality are TB (30%), Cryptococcal Meningitis (15%) Severe bacterial infections.

Image

Children (0-14) are disproportionately affected.

13% of deaths despite representing 4% of the disease burden.

Coverage of life-saving interventions remains suboptimal and inequitable in SSA, with gaps along the care cascade.

Image

AHD diagnosis.

CD4 testing <30%; Limited OI testing: TB, Cryptococcal Meningitis & Histoplasmosis (Unknown)
Image

Preventive treatment.

Limited prophylaxis: TPT among HIV- 58% 3; 3HP.
Image

ART coverage.

Children (0-14): <50%  vs Adults> 70%.
Pregnant women in SSA account for 50% of people not receiving ARTs.
Gender disparities: Men 78% vs Women 80%.

IMPAACT4HIV is dedicated to enhancing access to care and treatment for Advanced HIV Disease (AHD) across six high-burden African countries:

Côte d’Ivoire, Sierra Leone, the Democratic Republic of Congo (DRC), Nigeria, Mozambique, and South Africa.

Market-shaping interventions will negotiate pricing for new and existing tools, optimize innovation and responsive tool design, and improve access to and availability of affordable and high-quality diagnosis, prevention, and treatment options for those who need them.

Our goal is to effectively operationalize the STOPAIDS toolkit in these countries, ultimately improving health outcomes for those affected by advanced HIV disease.

Image

IMPAACT4HIV Consortium

The IMPAACT4HIV consortium comprises six partner organisations providing global and country-focused technical support across six countries in SSA.

Key
Paediatrics
Adolescents and adults
Paediatrics, adolescents and adults

IMPAACT4HIV is a Unitaid-funded project implemented by a consortium of six partners.

Unitaid

Role: Funder

Focus Countries:
Mozambique, South Africa, Nigeria, Cote D’Ivoire, The Democratic Republic of Congo (DRC) and Sierra Leone.

The Aurum Institute

Role: Consortium Lead
Technical lead: Market Access, Communities and Civil Societies Engagements (CCSE).

Focus Countries:
South Africa, Mozambique, Nigeria

Paediatric Adolescent Treatment Africa

Role: Communities and Civil Societies Engagements (CCSE).
Paediatrics advisory and technical support

Focus Countries:
South Africa, Mozambique, Cote D’Ivoire, Nigeria

Market Access Africa

Role: Market Access

Focus Countries:
Mozambique, South Africa, Nigeria, Cote D’Ivoire, The Democratic Republic of Congo (DRC) and Sierra Leone.

Centre for Integrated Health Programs

Role: Delivery Partner, Nigeria

Focus Countries:
Nigeria

Drugs for Neglected Diseases Initiative

Role: Implementing Partner

Focus Countries:
The Democratic Republic of Congo (DRC)

Solidarité Thérapeutique et Initiatives pour la Santé

Role: Implementing Partner

Focus Countries:
Cote D’Ivoire, Sierra Leone
© 2025 The Aurum Institute. All Rights Reserved.